ASX Announcement **23 September 2026**

Notice of Extraordinary General Meeting (EGM)

Genetic Signatures Limited (ASX:GSS) advises that the following documents relating to the Extraordinary General Meeting of the Company, to be held at 10:00am (Sydney time) on Wednesday, 28 October 2026, are attached:

- Notice of Extraordinary General Meeting
- Proxy Form
- Notice and Access Letter

.

This announcement has been authorised for release by the Board of Directors of Genetic Signatures Limited.

– END –

For further information, see our website (www.geneticsignatures.com) or contact us:

Sonya Tissera
Company Secretary
Genetic Signatures Limited

About Genetic Signatures

Genetic Signatures is a specialist molecular diagnostics company focused on the development and commercialisation of its proprietary platform technology, 3base®. Genetic Signatures designs and manufactures a suite of real-time Polymerase Chain Reaction (PCR) based products for the routine detection of infectious diseases under the EasyScreen™ brand. Genetic Signatures' proprietary 3base® platform technology provides high-volume hospital and pathology laboratories the ability to screen for a wide array of infectious pathogens, with a high degree of specificity, in a rapid throughput (time-to-result) environment. Genetic Signatures' current target markets are major hospital and pathology laboratories undertaking infectious disease screening.

GENETIC SIGNATURES LIMITED

ACN 095 913 205

NOTICE OF EXTRAORDINARY GENERAL MEETING

and

EXPLANATORY MEMORANDUM

and

PROXY FORM

DATE AND TIME OF MEETING:

WEDNESDAY, 28 OCTOBER 2026 AT 10.00am (Sydney time)

TO BE HELD AT
Gadens
Level 29, 8 Chifley Square
Sydney NSW 2000

The Directors consider that the Resolutions set out in this Notice of Meeting are NOT IN THE BEST INTERESTS of the Company or its Shareholders and recommend that Shareholders VOTE AGAINST these Resolutions.

THIS DOCUMENT IS IMPORTANT AND REQUIRES YOUR IMMEDIATE ATTENTION

These documents should be read in their entirety. If you are in any doubt as to what action you should take, you are recommended to seek your own advice from your accountant, solicitor or other duly authorised professional adviser.

DIRECTORS' STATEMENT TO SHAREHOLDERS

Dear Shareholders,

On behalf of the Board of Directors of Genetic Signatures Limited (ASX: GSS) (**Company** or **GSS**), we write to you in connection with the upcoming Extraordinary General Meeting of the Company (**EGM**) requisitioned by BCAL Diagnostics Limited (ASX: BCAL) (**BCAL**).

The resolutions set out in this Notice have been proposed by BCAL (**BCAL Spill Resolutions**), pursuant to requisition notices (**Requisition Notices**) served under section 249D of the *Corporations Act 2001* (Cth) (**Corporations Act**). The BCAL Spill Resolutions seek to fundamentally alter the composition of the Board by appointing Susan Forrester and John Melki (**Nominee Directors**) as Directors and removing Michael Aicher and Dr Jenny Harry as Directors.

The EGM represents an important point in the Company's development. The Board urges Shareholders to carefully assess whether the BCAL Spill Resolutions are in the best interests of the Company, particularly in circumstances where, the current Board is progressing a significant corporate transaction with Microba Life Sciences Limited (ASX: MAP) (**Microba**), which the Board believes presents a significant opportunity to build a larger, more diversified Australian diagnostics group with an expanded international presence.

We recommend that you vote against all Resolutions set out in this Notice of Meeting so that GSS can pursue the Proposed Merger with Microba – a transaction that we believe will create significantly greater shareholder value.

Microba Life Sciences – A significant strategic opportunity for GSS shareholders

As announced to ASX on 22 September 2026, the Board of GSS has agreed to an in-principle merger with Microba (**Proposed Merger**). This follows the Company's previous announcement on 26 August 2026, which informed the market of the ongoing merger discussions between GSS and Microba, in accordance with GSS's disclosed strategic plans of pursuing opportunities to scale in FY27.

The Board considers that the Proposed Merger will create a broader diagnostics group serving multiple stages of the gastrointestinal testing pathway, from rapid first-line pathogen detection through to advanced microbiome profiling. Importantly, this opportunity is supported by identifiable financial and operational synergies anticipated from the Proposed Merger.

The Company and Microba are proposing to implement the Proposed Merger pursuant to a scheme of arrangement (**Proposed Scheme**). A summary of the commercial terms of the Proposed Scheme is set out in the Company's ASX announcement dated 22 September 2026. As noted in the announcement, the Company will seek shareholder approval in accordance with the ASX Listing Rules to issue GSS securities to eligible Microba security holders pursuant to the terms of the Proposed Scheme.

The Proposed Scheme will be subject to a number of customary closing conditions, including obtaining the applicable MAP shareholder, regulatory, Court and other approvals. At this stage, the parties have not yet entered into binding documentation in relation to the Proposed Merger.

The Directors remain enthusiastic about the Proposed Merger with Microba and consider this a compelling strategic opportunity for the Company and all Shareholders. Microba is a business with a complementary product portfolio to GSS, and one of comparable scale, and the Board believes a merger would create a leading, scalable infectious disease diagnostics group.

BCAL's proposed changes to the Board

Approximately one week after GSS's market announcement regarding its discussions with Microba, BCAL, a GSS shareholder which recently acquired a relevant interest in GSS shares of just under than 20%, requisitioned the Company to call a Shareholder meeting for the purposes of considering resolutions seeking to remove two existing Directors and appoint the Nominee Directors of BCAL.

If all four BCAL Spill Resolutions are approved, the resulting three-person Board would comprise the two BCAL Nominee Directors and one continuing GSS Director. The Board considers that Shareholders should assess the proposed changes to the Board in the context of the Company's existing strategic direction, the Proposed Merger with Microba and the potential implications for any transaction with Microba.

In summary, the Board considers it is presently comprised of highly qualified directors whose experience is essential to implementing the Proposed Merger and leading the Company through its next stages of growth. Removing Mr Aicher and Dr Harry as Directors, and appointing the Nominee Directors, risks destabilising the Company's strategic direction at this critical time.

Your Directors are committed to acting in the best interests of the Company and **<u>all Shareholders</u>**, not just a single Shareholder.

We strongly encourage all Shareholders to **<u>VOTE AGAINST</u> all Resolutions**.

We urge you to read the accompanying Explanatory Memorandum in full and, if you are in any doubt as to the action you should take, we recommend you seek your own independent professional advice.

The Directors
Genetic Signatures Limited

Notice is given that the Extraordinary General Meeting (**EGM** or **Meeting**) of Genetic Signatures Limited (**GSS** or **Company**) will be held at:

Date	Wednesday, 28 October 2026
Time	10.00am (Sydney time)
Location	Gadens Level 29, 8 Chifley Square Sydney NSW 2000

The Explanatory Memorandum accompanying this Notice of Meeting provides additional information on the matters to be considered at the EGM. The Explanatory Memorandum and the Proxy Form are part of this Notice of Meeting.

This Extraordinary General Meeting has been convened at the requests of BCAL Diagnostics Limited (ACN 142 051 223) (ASX: BCAL) (**BCAL**), a Shareholder of the Company holding at least 5% of the votes that may be cast at a general meeting of the Company, pursuant to section 249D of the *Corporations Act 2001* (Cth) (**Corporations Act**) (**Requisition Notices**).

The Resolutions set out below have been proposed by BCAL (**BCAL Spill Resolutions**).

Certain capitalised terms in this Notice and Explanatory Statement are defined in Schedule 1, unless otherwise defined.

A. ITEMS OF BUSINESS

RESOLUTION 1: APPOINTMENT OF SUSAN MARGARET FORRESTER AS A DIRECTOR

To consider and, if thought fit, pass the following as an **ordinary resolution** of Shareholders of the Company:

> *"That, Susan Margaret Forrester, having consented to act as a director of the Company, be appointed as a director of the Company effective immediately on the passing of this resolution."*

The Board recommends that Shareholders vote **AGAINST** this resolution.

RESOLUTION 2: REMOVAL OF MICHAEL AICHER AS A DIRECTOR

To consider and, if thought fit, pass the following as an **ordinary resolution** of Shareholders of the Company:

> *"That, in accordance with section 203D(1) of the Corporations Act, Michael Aicher be removed as a director of the Company effective immediately on the passing of this resolution."*

The Board recommends that Shareholders vote **AGAINST** this resolution.

RESOLUTION 3: APPOINTMENT OF JOHN ROBERT MELKI AS A DIRECTOR

To consider and, if thought fit, pass the following as an **ordinary resolution** of Shareholders of the Company:

> *"That, John Robert Melki, having consented to act as a director of the Company, be appointed as a director of the Company effective immediately on the passing of this resolution."*

The Board recommends that Shareholders vote **AGAINST** this resolution.

RESOLUTION 4: REMOVAL OF DR JENNY HARRY AS A DIRECTOR

To consider and, if thought fit, pass the following as an **ordinary resolution** of Shareholders of the Company:

> *"That Jenny Harry be removed as a director of the Company effective immediately on the passing of this resolution."*

The Board recommends that Shareholders vote **AGAINST** this resolution.

B. OTHER INFORMATION

Entitlement to Attend and Vote

In accordance with regulation 7.11.37 of the *Corporations Regulations 2001* (Cth) the Board has determined that persons eligible to attend and vote at the Meeting as a Shareholder, are those who are registered Shareholders of the Company as at 10.00am (Sydney time) on Monday, 26 October 2026 (**Entitlement Time**) being two days before the Meeting.

This means that if you are not the registered holder of a share in the Company at the Entitlement Time, you will not be entitled to vote at the Meeting.

If more than one joint holder of shares is present at the Meeting (whether personally, by proxy or by attorney or by representative) and tenders a vote, only the vote of the joint holder whose name appears first on the register will be counted.

Voting by Proxy

If you are a Shareholder entitled to attend and vote, you may appoint an individual or a body corporate as a proxy. If a body corporate is appointed as a proxy, that body corporate must ensure that it appoints a corporate representative in accordance with section 250D of the Corporations Act to exercise its powers as proxy at the EGM.

A proxy need not be a Shareholder of the Company.

A Shareholder may appoint up to two proxies and specify the proportion or number of votes each proxy may exercise. If the Shareholder does not specify the proportion or number of votes to be exercised, each proxy may exercise half of the Shareholder's votes.

Transfer of non-Chair proxy to chair in certain circumstances

Section 250BC of the Corporations Act provides that, where an appointment of a non-Chair proxy specifies the way that the proxy is to vote on a particular resolution and:

a. a poll is duly demanded on the Resolution; and

b. either the proxy is not recorded as attending the Meeting; or

c. the proxy does not vote on the Resolution,

the Chair of the Meeting is taken, before voting on each Resolution closes, to have been appointed as the proxy for the purposes of voting on the Resolution at the Meeting.

Chair's voting intentions

The Chair of the Meeting intends to vote all available proxies **AGAINST** all Resolutions.

Any directed proxies that are not voted on a poll at the Meeting will automatically default to the Chair of the Meeting, who is required to vote proxies as directed.

Proxy Forms

To be effective, the Proxy Form must be completed, signed and lodged (together with the relevant original power of attorney or a certified copy if the proxy is signed by an attorney with the Company's Share Registry, as an original or by facsimile), **no later than 10.00am (Sydney time) on Monday, 26 October 2026** (**Proxy Deadline**).

Proxy Forms may be submitted in one of the following ways:

a. **Online** (preferred) via the Company's Share Registry website at www.votingonline.com.au/. Please refer to the Proxy Form for information; or

b. **By fax** to Boardroom Pty Ltd on +61 2 9290 9655; or

c. **By mail** to Boardroom Pty Ltd using the reply-paid envelope or GPO Box 3993, Sydney NSW 2001. Please allow sufficient time so that it reaches Boardroom Pty Ltd by the Proxy Deadline; or

d. **By hand delivery** to Boardroom Pty Ltd at Level 8, 210 George Street, Sydney, NSW 2000 (during business hours, Monday to Friday 9:00am – 5:00pm).

Proxy Forms and Powers of Attorney must be received by the Proxy Deadline.

Voting by Attorney

To vote by attorney at the Meeting, the original power of attorney or other authority (if any) under which the instrument is signed (or a certified copy of that power of attorney or other authority) must be received by the Company **no later than 10.00am (Sydney time) on Monday, 26 October 2026**, being 48 hours before the EGM.

Corporate Representatives

A body corporate which is a Shareholder, or which has been appointed as a proxy, is entitled to appoint any person to act as its representative at the EGM. The appointment of the representative must comply with the requirements under section 250D of the Corporations Act. The representative should bring to the EGM a properly executed letter or other document confirming its authority to act as the company's representative.

Shareholder Questions

Shareholders who are unable to attend the Meeting or who may prefer to register questions in advance are invited to do so. If you wish to submit a question in writing to the Chair, please email them to the Company Secretary, Sonya Tissera (Sonya.Tissera@vistra.com) **by 5:00pm (Sydney time) on Tuesday, 20 October 2026**.

Questions will be collated, and during the EGM, the Chair will seek to address as many of the more frequently raised topics as possible. However, there may not be sufficient time available at the EGM to address all topics raised. Please note that individual responses will not be sent to Shareholders.

BY ORDER OF THE BOARD

Sonya Tissera
Company Secretary
23 September 2026

EXPLANATORY MEMORANDUM

This Explanatory Memorandum has been prepared for the information of Shareholders of the Company in relation to the business to be conducted at the EGM to be held on Wednesday, 28 October 2026 at 10.00am (Sydney time).

The purpose of this Explanatory Memorandum is to provide background to the Meeting and the BCAL Spill Resolutions, and to provide Shareholders with information that your Directors consider is reasonably required by Shareholders to decide how to vote upon the Resolutions.

Save in respect of Resolution 2, in relation to which Mr Aicher abstains from making a recommendation, and Resolution 4, in relation to which Dr Harry abstains from making a recommendation, the Directors recommend Shareholders vote against the BCAL Spill Resolutions and intend to vote all shares they hold against the BCAL Spill Resolutions.

All BCAL Spill Resolutions are ordinary resolutions, which require a simple majority of votes cast by Shareholders present and entitled to vote on the resolution.

BACKGROUND TO BCAL SPILL RESOLUTIONS

BCAL holds more than 5% of the Company's share capital and is therefore permitted to request the Company to convene a general meeting of shareholders.

On Thursday, 3 September 2026, the Company received the First Requisition Notice from BCAL. The purpose and effect of the First Requisition Notice is to require the Company to call and hold this Meeting, to put to Shareholders the BCAL Spill Resolutions for:

- *Resolution 1* - the appointment of Susan Margaret Forrester as a director of the Company;
- *Resolution 2* - the removal of Michael (Mike) Aicher as a director of the Company; and
- *Resolution 3* - the appointment of John Robert Melki as a director of the Company.

On Tuesday, 15 September 2026, the Company received the Second Requisition Notice from BCAL. The purpose and effect of the Second Requisition Notice is to further require the Company to put to Shareholders the resolution for the removal of Dr Jenny Harry as a director of the Company (**Resolution 4**).

Rule 6.10(f) of the Company's Constitution provides that, in the case of an equality of votes, the Chairperson of the Board has the casting vote. The Board notes that had BCAL not issued the Second Requisition Notice, then in a scenario where Resolutions 1 to 3 were approved by Shareholders, the Board would have been comprised of four directors, and the incumbent Chairperson would have had the casting vote. To this end, the Board suspects that BCAL has called for the removal of Dr Harry so that it's Nominee Directors can collectively appoint the Chairperson of the Board and pass Board resolutions as they see fit.

In compliance with the Requisition Notices, the Company has issued this Notice of Meeting in which the BCAL Spill Resolutions have been included as items of business.

RESOLUTIONS 1 AND 3: APPOINTMENT OF SUSAN MARGARET FORRESTER AND JOHN ROBERT MELKI AS DIRECTORS

The Board respects the rights of Shareholders to requisition resolutions and put forward proposals to change the composition of the Board. However, the Company considers that the BCAL Spill Resolutions will not serve the best interests of the Company and therefore should be voted against by Shareholders for the reasons outlined in this Explanatory Memorandum.

BCAL's Acquisition of Shares in GSS

As Shareholders will be aware from the Company's announcement on 3 September 2026 and the substantial holding notices lodged by BCAL on 2 July 2026 and 26 August 2026, BCAL has acquired a substantial shareholding in GSS since July. According to its substantial holding notices, BCAL first acquired a relevant interest in GSS shares of approximately 10.2% in July 2026 and subsequently increased its relevant interest to just under 18.5% in August

2026. The Company has previously disclosed concerns regarding the circumstances of those acquisitions, including in relation to BCAL's substantial holder disclosures.

The accumulation of a significant shareholding, coupled with the Requisition Notices, raises questions about BCAL's intentions with respect to the direction of the Company that have not been addressed by BCAL.

Effect of the BCAL Spill Resolutions on Board composition

When BCAL served the First Requisition Notice on 3 September 2026, it sought the appointment of the two Nominee Directors and the removal of one existing Director, being Mr Aicher. The proposed resolution contained in its Second Requisition Notice, which BCAL served on the Company 12 days later, seeks to remove an additional existing Director, being Dr Harry.

The Company notes that, if all four of the BCAL Spill Resolutions are approved, the reconstituted Board will be comprised of three Directors, two of whom are the Nominee Directors appointed by BCAL. To the extent that the Nominee Directors are aligned, they will have a two-thirds majority and effective control of the reconstituted Board.

The Directors consider a two-thirds majority is wholly inappropriate and constitutes a disproportionate representation for a Shareholder with a relevant interest of less than 20%.

Uncertainty regarding BCAL's intentions

In its public announcement dated 2 July 2026 and investor presentation dated 3 September 2026, BCAL has referred to a potential "to explore partnership, pipeline and channel opportunities" and "leverage complementary capabilities" as expected benefits of its investment in GSS. However, these stated intentions are inconsistent with BCAL's actions to date.

GSS notes that the only substantive communications the Company has received from BCAL have been the Requisition Notices, seeking the removal of two of the Company's Directors and the appointment of BCAL's own Nominee Directors, which places the Nominee Directors in a position where they will collectively be able to carry Board resolutions.

The actions of BCAL are not consistent with those of a genuine partner and raises serious questions about BCAL's willingness to respect the independence of the Board or to act in the interests of all Shareholders as a whole. It remains unclear whether BCAL is genuinely interested in acquiring control of GSS or whether the Requisition Notices are being used as a mechanism to disrupt the Company's growth strategies.

The Board queries the timing of BCAL's actions, noting that BCAL served notice on GSS of its intention to move a resolution to remove an existing Director only one week after the Company announced to ASX that it had entered into discussions with Microba regarding a potential merger. The Directors consider the proximity of these events raises a reasonable inference that BCAL's requisition may be motivated, at least in part, by a desire to delay or frustrate a merger with Microba, rather than to advance the interests of all Shareholders as a whole.

In light of the above, the Directors are further concerned that, if the BCAL Spill Resolutions are passed and BCAL subsequently seeks to engage with the Company regarding potential commercial arrangements or collaborations, the Nominee Directors may not be best placed to independently negotiate arm's-length agreements with BCAL on behalf of the Company, in a manner that prioritises the interests of all Shareholders.

Scale comparison: GSS, Microba and BCAL

The following table sets out a comparison of the quarterly revenue reported in the Quarterly Activities Reports and Appendices 4C (**Reports**) of GSS, Microba and BCAL for FY25 and FY26.

	FY25 Q1	FY25 Q2	FY25 Q3	FY25 Q4	FY26 Q1	FY26 Q2	FY26 Q3	FY26 Q4
Receipts from Customers ($A'000)								
GSS	$7,006	$3,302	$4,251	$3,609	$5,597	$4,573	$3,657	$2,990
Microba	$5,067	$3,874	$4,233	$3,996	$4,234	$3,591	$3,977	$3,950
BCAL	Nil	Nil	Nil	$22	$21	$1	$110	$11
Consolidated revenue								
GSS	$15,900,000				$14,840,000			
Microba	$15,669,089				$14,758,461			
BCAL	$21,637				$182,510			

The revenue data demonstrates that Microba is a business of comparable scale to GSS, whereby both companies generated approximately $15 million in annual revenue in each of FY25 and FY26. By contrast, BCAL generated total revenue of only $0.18 million in FY26.

These revenue figures reinforce the Board's view that a merger with Microba represents a compelling strategic opportunity to create a combined group with the financial scale and diversified revenue base necessary to accelerate growth and deliver long-term value for Shareholders. Notwithstanding that BCAL has not made its intentions with respect to the Company known at this stage, a combination with BCAL, by comparison, would not provide any perceived financial or strategic benefits for GSS.

The additional benefits of the Proposed Merger with Microba are discussed in GSS's announcement of 22 September 2026.

The Board is currently comprised of highly qualified and capable directors with relevant experience that will be essential to leading GSS through the next stages of the Company's growth. Appointing the two Nominee Directors would significantly reconfigure the Board, which has the potential to destabilise its strategic direction.

The Directors are of the view that it is in the best interests of <u>all Shareholders</u> (other than, perhaps, BCAL), that the Board be allowed to continue its leadership of the Company in its current composition.

The Board therefore **<u>recommends Shareholders VOTE AGAINST Resolutions 1 and 3.</u>**

RESOLUTIONS 2 AND 4: REMOVAL OF MIKE AICHER AND DR JENNY HARRY AS DIRECTORS

Mr Aicher has over 30 years of industry experience and has served the Company as an Executive Director since January 2014.

Alongside his role with GSS, he currently serves as Executive Chairman of SemiconBio Inc., and as a director of three other diagnostics and medtech companies: Techcyte, SOLVD Health and PixCell Medical.

Mr Aicher previously served on the Board of Fabric Genomics, which analyses and interprets genomic information. Fabric Genomics was acquired by GeneDX (NASDAQ:WGS), and was a Board member of Ariosa, a prenatal testing molecular diagnostics company until its acquisition by Roche. He co-founded and served as National Genetics Institute's (NGI) CEO from 1991 to 2013. NGI became a wholly owned subsidiary of Laboratory Corporation of America (NYSE: LH) in 2000, where he ran the company's "Esoteric Business Units", which generated over $1 billion in annual revenue. He holds a Bachelor of Science in Business Administration from the University of Redlands and is a certified Global Biotechnology Executive from the University of California, Berkeley. He also received Ernst and Young's "Entrepreneur of the Year" award for emerging technologies.

Dr Harry has 25 years' experience in executive roles and as an independent Director in leading early-stage companies to develop and commercialise innovative products. She co-founded Proteome Systems Limited with the team who pioneered the scientific field of proteomics and commercialised a suite of disruptive technologies including reagents, instrumentation and software in Australia, the USA and Japan. As CEO of Tyrian Diagnostics Ltd she secured agreements with multi-national companies for the development and commercialisation of agricultural and clinical diagnostic products. In addition to serving on the Boards of ASX listed companies, Dr Harry is also a Non-Executive Director of US-based Lumitron Technologies, Inc. Dr Harry holds a PhD in developmental biology, is a graduate of the Harvard Business School's General Management Program and the Australian Institute of Company Directors.

Dr Harry was appointed as a Non-Executive Director of the Company in October 2024 and currently serves as the Chair of the Nomination and Remuneration Committee.

The contributions and the depth of the experience of these two Directors cannot be easily replaced.

The Directors believe that the individuals who comprise the current Board each bring an appropriate cross-section of skills and experience relevant to GSS's business. The removal of Mr Aicher and Dr Harry, along with the appointment of two Nominee Directors, would fundamentally change the composition of the Board, which may introduce instability and impede the strategic direction of the Company.

The Directors are of the view that the Board in its current composition, supported by Mr Aicher's strategic leadership and Dr Harry's expertise in the development and commercialisation of innovative technologies, is well-placed to continue to act in the best interests of the Company and all Shareholders.

Therefore, the Board:

- recommends Shareholders **VOTE AGAINST** Resolution 2, with Mike Aicher abstaining; and
- recommends Shareholders **VOTE AGAINST** Resolution 4, with Dr Jenny Harry abstaining.

Voting on Resolutions 1 to 4 in accordance with the directors' recommendations will result in an unchanged Board.

SCHEDULE 1: GLOSSARY

In this Notice of Meeting and Explanatory Memorandum the following expressions have the following meanings:

"BCAL"	means BCAL Diagnostics Limited ACN 142 051 223 (ASX: BCAL).
"BCAL Spill Resolutions"	means Resolutions 1 to 4, proposed by BCAL in the Requisition Notices.
"Board"	means the board of Directors of the Company.
"Chair"	means the Chair of the Meeting.
"Company" or "GSS"	means Genetic Signatures Limited ACN 095 913 205 (ASX: GSS).
"Corporations Act"	means *Corporations Act 2001* (Cth).
"Director"	means a director of the Company.
"EGM" or "Meeting"	means the Extraordinary General Meeting of the Company to be held on Wednesday, 28 October 2026.
"Explanatory Memorandum"	means the explanatory memorandum accompanying this Notice.
"First Requisition Notice"	means the notice given by BCAL to GSS pursuant to section 249D of the Corporations Act dated 3 September 2026.
"FY25"	means the financial year ending 30 June 2025.
"FY26"	means the financial year ending 30 June 2026.
"FY27"	means the financial year ending 30 June 2027.
"Microba"	means Microba Life Sciences Limited ACN 617 096 652 (ASX: MAP).
"Nominee Directors"	means Susan Margaret Forrester and John Robert Melki.
"Proposed Merger"	has the meaning given to that term in the Directors' Statement to Shareholders set out on page 2.
"Proposed Scheme"	has the meaning given to that term in the Directors' Statement to Shareholders set out on page 2.
"Requisition Notices"	means the First Requisition Notice and the Second Requisition Notice.
"Second Requisition Notice"	means the notice given by BCAL to GSS pursuant to section 249D of the Corporations Act dated 15 September 2026.
"Shareholder"	means a shareholder of the Company.

Genetic Signatures

All Correspondence to:

By Mail Boardroom Pty Limited
GPO Box 3993
Sydney NSW 2001 Australia

By Fax: +61 2 9290 9655

Online: www.boardroomlimited.com.au

By Phone: (within Australia) 1300 737 760
(outside Australia) +61 2 9290 9600

YOUR VOTE IS IMPORTANT

For your vote to be effective it must be recorded before **10:00am (Sydney time) on Monday, 26 October 2026.**

TO APPOINT A PROXY ONLINE

STEP 1: VISIT https://www.votingonline.com.au/gssegm2026

STEP 2: Enter your Postcode OR Country of Residence (if outside Australia)

STEP 3: Enter your Voting Access Code (VAC):

BY SMARTPHONE

Scan QR Code using smartphone
QR Reader App

TO VOTE BY COMPLETING THE PROXY FORM

STEP 1 APPOINTMENT OF PROXY

Indicate who you want to appoint as your Proxy.
If you wish to appoint the Chair of the Meeting as your proxy, mark the box. If you wish to appoint someone other than the Chair of the Meeting as your proxy please write the full name of that individual or body corporate. If you leave this section blank, or your named proxy does not attend the meeting, the Chair of the Meeting will be your proxy. A proxy need not be a securityholder of the company. Do not write the name of the issuer company or the registered securityholder in the space.

Appointment of a Second Proxy

You are entitled to appoint up to two proxies to attend the meeting and vote. If you wish to appoint a second proxy, an additional Proxy Form may be obtained by contacting the company's securities registry or you may copy this form.

To appoint a second proxy you must:
(a) complete two Proxy Forms. On each Proxy Form state the percentage of your voting rights or the number of securities applicable to that form. If the appointments do not specify the percentage or number of votes that each proxy may exercise, each proxy may exercise half your votes. Fractions of votes will be disregarded.
(b) return both forms together in the same envelope.

STEP 2 VOTING DIRECTIONS TO YOUR PROXY

To direct your proxy how to vote, mark one of the boxes opposite each item of business. All your securities will be voted in accordance with such a direction unless you indicate only a portion of securities are to be voted on any item by inserting the percentage or number that you wish to vote in the appropriate box or boxes. If you do not mark any of the boxes on a given item, your proxy may vote as he or she chooses. If you mark more than one box on an item for all your securities your vote on that item will be invalid.

Proxy which is a Body Corporate

Where a body corporate is appointed as your proxy, the representative of that body corporate attending the meeting must have provided an "Appointment of Corporate Representative" prior to admission. An Appointment of Corporate Representative form can be obtained from the company's securities registry.

STEP 3 SIGN THE FORM

The form **must** be signed as follows:
Individual: This form is to be signed by the securityholder.
Joint Holding: where the holding is in more than one name, all the securityholders should sign.
Power of Attorney: to sign under a Power of Attorney, you must have already lodged it with the registry. Alternatively, attach a certified photocopy of the Power of Attorney to this form when you return it.
Companies: this form must be signed by a Director jointly with either another Director or a Company Secretary. Where the company has a Sole Director who is also the Sole Company Secretary, this form should be signed by that person. **Please indicate the office held by signing in the appropriate place.**

STEP 4 LODGEMENT

Proxy forms (and any Power of Attorney under which it is signed) must be received no later than 48 hours before the commencement of the meeting, therefore by **10:00am (Sydney time) on Monday, 26 October 2026.** Any Proxy Form received after that time will not be valid for the scheduled meeting.

Proxy forms may be lodged using the enclosed Reply Paid Envelope or:

Online https://www.votingonline.com.au/gssegm2026

By Fax + 61 2 9290 9655

By Mail Boardroom Pty Limited
GPO Box 3993,
Sydney NSW 2001 Australia

In Person Boardroom Pty Limited
Level 8, 210 George Street
Sydney NSW 2000 Australia

Attending the Meeting

If you wish to attend the meeting please bring this form with you to assist registration.

Genetic Signatures Limited
ACN 095 913 205

☐ **Your Address**
This is your address as it appears on the company's share register. If this is incorrect, please mark the box with an "X" and make the correction in the space to the left. Securityholders sponsored by a broker should advise their broker of any changes.
Please note, you cannot change ownership of your securities using this form.

PROXY FORM

STEP 1 APPOINT A PROXY

I/We being a member/s of **Genetic Signatures Limited** (Company) and entitled to attend and vote hereby appoint:

☐ the **Chair of the Meeting (mark box)**

OR if you are **NOT** appointing the Chair of the Meeting as your proxy, please write the name of the person or body corporate (excluding the registered securityholder) you are appointing as your proxy below

or failing the individual or body corporate named, or if no individual or body corporate is named, the Chair of the Meeting as my/our proxy at the Extraordinary General Meeting of the Company to be held at the **Gadens, Level 29, 8 Chifley Square, Sydney NSW 2000 on Wednesday, 28 October, 2026 at 10:00am (Sydney time)** and at any adjournment of that meeting, to act on my/our behalf and to vote in accordance with the following directions or if no directions have been given, as the proxy sees fit.

The Chair of the Meeting intends to vote undirected proxies **Against** each of the items of business.

STEP 2 VOTING DIRECTIONS

* If you mark the Abstain box for a particular item, you are directing your proxy not to vote on your behalf on a show of hands or on a poll and your vote will not be counted in calculating the required majority if a poll is called.

		For	Against	Abstain*
Resolution 1	Appointment of Susan Margaret Forrester as a Director	☐	☐	☐
Resolution 2	Removal of Michael Aicher as a Director	☐	☐	☐
Resolution 3	Appointment of John Robert Melki as a Director	☐	☐	☐
Resolution 4	Removal of Dr Jenny Harry as a Director	☐	☐	☐

STEP 3 SIGNATURE OF SECURITYHOLDERS

This form must be signed to enable your directions to be implemented.

Individual or Securityholder 1	Securityholder 2	Securityholder 3
Sole Director and Sole Company Secretary	Director	Director / Company Secretary

Contact Name……………………………………………....   Contact Daytime Telephone……………………..............................   Date / / 2026

Genetic Signatures

23 September 2026

Extraordinary General Meeting of Genetic Signatures Limited
to be held on Wednesday 28 October 2026

Dear Shareholder

The Extraordinary General Meeting (EGM or Meeting) of Genetic Signatures Limited will be held at 10:00am (Sydney time) on Wednesday, 28 October 2026 at the offices of **Gadens, Level 29, 8 Chifley Square, Sydney NSW 2000.**

The EGM will be held as a physical meeting, whereby shareholders can attend in person. Registration opens from 9:30am (Sydney time) on the day of the Meeting. Shareholders who are not able to attend the Meeting in person are directed to lodge their votes by proxy as soon as possible. Shareholders who are not able to attend the Meeting but who wish to ask questions of the Company can do so by submitting their questions by email to Sonya.Tissera@vistra.com by no later than 5:00pm (Sydney time) on Tuesday, 20 October 2026.

Shareholders are strongly recommended to submit their votes by proxy to ensure that their votes are counted. Instructions on how to submit votes by proxy are contained within the Notice of Extraordinary General Meeting.

To view the Notice of Extraordinary General Meeting, please use the following link:

https://geneticsignatures.com/au/investors/announcements/

VOTING IS NOW OPEN. To vote online, please follow the instructions below:

- STEP 1: Visit https://www.votingonline.com.au/gssegm2026
- STEP 2: Enter your Postcode (if within Australia) OR Country of Residence (if outside Australia)
- STEP 3: Enter your Voting Access Code (VAC) as contained in the attached Proxy Form
- STEP 4: Follow the prompts to vote on each resolution

Important Note: For your voting instructions to be valid and counted towards this Meeting, please ensure that your online lodgement is received no later than 10:00am (Sydney time) on Monday, 26 October 2026. Voting instructions received after this time will not be valid for the scheduled Meeting.

If you have any queries regarding your shareholding or the upcoming Extraordinary General Meeting of Genetic Signatures Limited, please contact Boardroom Pty Ltd on 1300 737 760 (within Australia) or +61 2 9290 9600 (outside Australia).

Yours faithfully

Sonya Tissera
Company Secretary
Genetic Signatures Limited